Skip to main content
Fig. 5 | Biomarker Research

Fig. 5

From: Co-expression and clinical utility of AR-FL and AR splice variants AR-V3, AR-V7 and AR-V9 in prostate cancer

Fig. 5

AR-FL and AR-V distribution and expression in n = 94 mCRPC patients. A Shown are the percentages of 4 different subgroups (CTC-, CTC + /AR-FL-/AR-V-, CTC + /AR-FL + /AR-V- and CTC + /AR-FL + /AR-V + ; left panel) as well as detailed distribution of AR-V numbers in CTC + /AR-FL + /AR-V + patients (right panel) at different lines of treatment. B Transcript copy number analyses of AR-FL copy numbers (left panel) and AR-V copy numbers (right panel) (* represents < 0.05, ** < 0.01)

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us